NSI 777
Alternative Names: NSI-777Latest Information Update: 28 Apr 2021
At a glance
- Originator Neuralstem
- Developer John Hopkins University; Seneca Biopharma
- Class Neural stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Demyelinating disorders; Multiple sclerosis
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Demyelinating disorders in USA (Parenteral)
- 28 Apr 2021 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (Parenteral)
- 27 Apr 2021 Leading BioSciences has merged with Seneca Biopharma to form Palisade Bio